Cargando…
Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives
Targeted agents form the backbone of most therapeutic strategies in advanced renal cell carcinoma (aRCC) but ultimately resistance develops and toxicity often leads to discontinuation of treatment, limiting the clinical benefits of these treatments. Nivolumab, a fully human IgG4 anti-PD-1 antibody,...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Codon Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806048/ https://www.ncbi.nlm.nih.gov/pubmed/29468108 http://dx.doi.org/10.15586/jkcvhl.2018.102 |